NasdaqCM:CYCC

Stock Analysis Report

Executive Summary

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

Snowflake

Flawless balance sheet with questionable track record.


Similar Companies

ArQule

NasdaqGM:ARQL

Share Price & News

How has Cyclacel Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYCC's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-5.8%

CYCC

1.7%

US Biotechs

0.4%

US Market


1 Year Return

-65.3%

CYCC

8.4%

US Biotechs

13.1%

US Market

Return vs Industry: CYCC underperformed the US Biotechs industry which returned 8.4% over the past year.

Return vs Market: CYCC underperformed the US Market which returned 13.1% over the past year.


Shareholder returns

CYCCIndustryMarket
7 Day-5.8%1.7%0.4%
30 Day-1.4%10.0%4.0%
90 Day-16.3%7.1%7.4%
1 Year-65.3%-65.3%9.5%8.4%15.6%13.1%
3 Year-89.5%-89.5%14.9%11.2%48.2%38.6%
5 Year-98.9%-98.9%5.2%0.2%62.6%44.6%

Price Volatility Vs. Market

How volatile is Cyclacel Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cyclacel Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

0.42x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYCC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYCC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYCC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: CYCC is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYCC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYCC is good value based on its PB Ratio (0.4x) compared to the US Biotechs industry average (2.9x).


Next Steps

Future Growth

How is Cyclacel Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

47.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYCC is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYCC is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYCC is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYCC is forecast to have no revenue next year.

High Growth Revenue: CYCC is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYCC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cyclacel Pharmaceuticals performed over the past 5 years?

15.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYCC has high quality earnings.

Growing Profit Margin: CYCC's current net profit margins (-5275.3%) are higher than last year (-7112.8%).


Past Earnings Growth Analysis

Earnings Trend: CYCC is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year.

Accelerating Growth: Unable to compare CYCC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (86.5%).


Return on Equity

High ROE: CYCC has a negative Return on Equity (-49.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Cyclacel Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: CYCC's short term assets ($18.2M) exceeds its short term liabilities ($2.5M)

Long Term Liabilities: CYCC's short term assets (18.2M) exceeds its long term liabilities (1.2M)


Debt to Equity History and Analysis

Debt Level: CYCC is debt free.

Reducing Debt: CYCC has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CYCC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CYCC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYCC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CYCC has sufficient cash runway for 1.438559 years if free cash flow continues to grow at historical rates of 13.1% each year.


Next Steps

Dividend

What is Cyclacel Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.1%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CYCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CYCC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYCC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYCC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYCC's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cyclacel Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

13.7yrs

Average board tenure


CEO

Spiro Rombotis (60yo)

22.3yrs

Tenure

US$752,824

Compensation

Mr. Spiro George Rombotis has been President of Cyclacel Pharmaceuticals Inc. (formerly, Cyclacel Group Plc) since August 1997 and has been its Founding Chief Executive Officer since joining in August 1997 ...


CEO Compensation Analysis

Compensation vs Market: Spiro's total compensation ($USD752.82K) is above average for companies of similar size in the US market ($USD509.90K).

Compensation vs Earnings: Spiro's compensation has been consistent with company performance over the past year.


Board Age and Tenure

13.7yrs

Average Tenure

70yo

Average Age

Experienced Board: CYCC's board of directors are seasoned and experienced ( 13.7 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.6%.


Management Team

  • Spiro Rombotis (60yo)

    President

    • Tenure: 22.3yrs
    • Compensation: US$752.82k
  • Paul McBarron (58yo)

    Executive VP of Finance

    • Tenure: 13.7yrs
    • Compensation: US$387.99k
  • Robert Westwood (75yo)

    Head of Preclinical Development and Vice President of Chemistry & Preclinical Development

    • Tenure: 0yrs
  • Gill Christie (62yo)

    Director of Human Resources

    • Tenure: 0yrs
  • Judy Chiao (59yo)

    Vice President of Clinical Development & Regulatory Affairs

    • Tenure: 14.5yrs
    • Compensation: US$529.73k

Board Members

  • Sam Barker (76yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: US$67.95k
  • John Michael Banham (78yo)

    Non-Executive Director

    • Tenure: 13.7yrs
    • Compensation: US$69.37k
  • David U'Prichard (70yo)

    Independent Chairman

    • Tenure: 0yrs
    • Compensation: US$100.28k
  • Chris Henney (78yo)

    Independent Vice Chairman

    • Tenure: 0yrs
    • Compensation: US$88.87k
  • Spiro Rombotis (60yo)

    President

    • Tenure: 22.3yrs
    • Compensation: US$752.82k
  • Paul McBarron (58yo)

    Executive VP of Finance

    • Tenure: 13.7yrs
    • Compensation: US$387.99k
  • Edward Sikora (69yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Michel Marty

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Kenneth Harrap

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Stanley Kaye

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Cyclacel Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cyclacel Pharmaceuticals, Inc.
  • Ticker: CYCC
  • Exchange: NasdaqCM
  • Founded: 1992
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.616m
  • Shares outstanding: 17.20m
  • Website: https://www.cyclacel.com

Number of Employees


Location

  • Cyclacel Pharmaceuticals, Inc.
  • 200 Connell Drive
  • Suite 1500
  • Berkeley Heights
  • New Jersey
  • 7922
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYCC.PNasdaqCM (Nasdaq Capital Market)PFD CONV EX 6%USUSDOct 2004
CYCCNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDMar 2006
UXI3DB (Deutsche Boerse AG)YesCommon StockDEEURMar 2006

Biography

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company’s oncology development programs incl ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/11/13 23:50
End of Day Share Price2019/11/13 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.